Xeris Biopharma (XERS Quick QuoteXERS - Free Report) reported $83.13 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 38.3%. EPS of $0.01 for the same period compares to -$0.06 a year ago.

The reported revenue represents a surprise of +3.88% over the Zacks Consensus Estimate of $80.03 million. With the consensus EPS estimate being $0, the company has not delivered EPS surprise.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Xeris Biopharma performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Product Revenue- Gvoke: $20.8 million compared to the $21.94 million average estimate based on four analysts.
• Product Revenue- Recorlev: $49.77 million versus the four-analyst average estimate of $44.78 million.
• Revenue- Royalty, contract and other: $0.67 million versus the four-analyst average estimate of $1.85 million.
• Revenue- Product revenue, net: $82.45 million compared to the $78.19 million average estimate based on four analysts.
• Product Revenue- Keveyis: $11.89 million versus $11.47 million estimated by four analysts on average.

View all Key Company Metrics for Xeris Biopharma here>>>

Shares of Xeris Biopharma have returned +7.6% over the past month versus the Zacks S&P 500 composite's +11.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.